Curated News
By: NewsRamp Editorial Staff
September 23, 2026
Onco-Innovations & Redwood AI Win Terry Fox Grant for AI Oncology Platform
TLDR
- Onco-Innovations and Redwood AI secured a Terry Fox grant, covering up to 25 percent of a $3.5 million budget for their SynoGraph oncology platform.
- SynoGraph uses federated learning and causal AI to predict first-in-human clinical outcomes from preclinical and real-world clinico-genomic data.
- The collaboration aims to accelerate cancer treatment development, potentially improving patient outcomes and advancing oncology research through innovative AI technology.
- The project combines AI, quantum cybersecurity, and genomics, offering a fascinating glimpse into the future of personalized medicine and data-driven healthcare.
Impact - Why it Matters
This grant and collaboration signify a major step forward in leveraging artificial intelligence to predict clinical outcomes and accelerate oncology drug development. By integrating federated learning and causal AI, the SynoGraph platform could reduce the time and cost of bringing new cancer therapies to market, ultimately benefiting patients through faster access to innovative treatments. The involvement of prestigious academic institutions and the Terry Fox Research Institute underscores the scientific rigor and potential impact of this project. As AI continues to revolutionize healthcare, this partnership exemplifies how industry-academia collaborations can drive meaningful advancements in cancer research and treatment.
Summary
Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF), in partnership with Canada’s Michael Smith Genome Sciences Centre and Centre de recherche du CHU de Québec-Université Laval, have been awarded a competitive Digital Health Innovation Fund grant from the Terry Fox Research Institute. The reimbursement-based grant will cover up to 25% of an estimated $3.5 million project budget to support the development of the Onco SynoGraph AI-driven oncology platform. This collaboration aims to enhance the platform using federated learning and causal AI to predict first-in-human clinical outcomes from preclinical studies and real-world clinico-genomic data, potentially streamlining drug development and improving patient outcomes.
Redwood AI will contribute proprietary data integration and physicochemical modelling methods, while the academic partners will provide clinico-genomic and imaging data. Onco-Innovations will supply its causal AI methods and federated pipeline development. The project underscores the growing role of AI in oncology and the importance of collaborative efforts between industry and academia. Onco-Innovations, a Canadian company dedicated to cancer research, holds an exclusive worldwide licence to patented technology for therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. Redwood AI develops advanced AI and cybersecurity solutions for defence, public safety, and life sciences. The grant from the Terry Fox Research Institute, a leading Canadian cancer research organization, highlights the potential of the SynoGraph platform to transform oncology drug development.
For more details, visit the full press release at https://ibn.fm/ySIj9. Investors can find updates on Onco-Innovations in the company’s newsroom at https://ibn.fm/ONNVF. The news was disseminated by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations & Redwood AI Win Terry Fox Grant for AI Oncology Platform
